猴痘的临床表现与诊疗随访

doi:10.35541/cjd.20220688

Abstract

Abstract: 【Abstract】 The world is suffering from the monkeypox epidemic, and China is facing a great risk of monkeypox importation. Understanding and mastering clinical manifestations, diagnosis and treatment of monkeypox is one of the important measures to respond to future crises. This review summarizes updated guidelines and relevant studies, and covers main clinical manifestations, diagnosis, treatment and follow-up of monkeypox patients, as well as management of special populations, aiming to provide references for clinicians and prevention workers.

Key words: Monkeypox, Diagnosis, Treatment

Du Fangzhi, Zhang Xu, Wang Qianqiu. Monkeypox: clinical manifestations, diagnosis, treatment and follow-up[J]. Chinese Journal of Dermatology, 2023, 56(1): 76-81.doi:10.35541/cjd.20220688

References ［43］

［1］	Shchelkunov SN, Totmenin AV, Babkin IV, et al. Human monkeypox and smallpox viruses: genomic comparison［J］. FEBS Lett, 2001,509（1）:66⁃70. doi: 10.1016/s0014⁃5793（01）03144⁃1.
［2］	McCollum AM, Damon IK. Human monkeypox［J］. Clin Infect Dis, 2014,58（2）:260⁃267. doi: 10.1093/cid/cit703.
［3］	American College of Emergency Physicians. ACEP monkeypox field guide［EB/OL］. （2022⁃07⁃08）［2022⁃11⁃02］. https://www.acep.org/monkeypox⁃field⁃guide/cover⁃page/.
［4］	Centers for Disease Control and Prevention. About Monkeypox［EB/OL］. （Updated 2022⁃07⁃22）［2022⁃11⁃02］. https://www.cdc.gov/poxvirus/monkeypox/about.html.
［5］	Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox⁃a potential threat? A systematic review［J/OL］. PLoS Negl Trop Dis, 2022,16（2）:e0010141. doi: 10.1371/journal.pntd.0010141.
［6］	Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis［J］. Lancet Infect Dis, 2004,4（1）:15⁃25. doi: 10.1016/s1473⁃3099（03）00856⁃9.
［7］	Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries ⁃ April⁃June 2022［J］. N Engl J Med, 2022,387（8）:679⁃691. doi: 10.1056/NEJMoa22 07323.
［8］	Orviz E, Negredo A, Ayerdi O, et al. Monkeypox outbreak in Madrid （Spain）: clinical and virological aspects［J］. J Infect, 2022,85（4）:412⁃417. doi: 10.1016/j.jinf.2022.07.005.
［9］	Jezek Z, Szczeniowski M, Paluku KM, et al. Human monkeypox: clinical features of 282 patients［J］. J Infect Dis, 1987,156（2）:293⁃298. doi: 10.1093/infdis/156.2.293.
［10］	Yinka⁃Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 2017⁃18: a clinical and epidemiological report［J］. Lancet Infect Dis, 2019,19（8）:872⁃879. doi: 10.1016/S1473⁃3099（19）30294⁃4.
［11］	Centers for Disease Control and Prevention. Case definitions for use in the 2022 monkeypox response［EB/OL］. （Updated 2022⁃07⁃22）［2022⁃11⁃02］. https://www.cdc.gov/poxvirus/monkeypox/clinicians/case⁃definition.html.
［12］	Peterson E, Kantele A, Koopmans M, et al. Human monkeypox: epidemiological and clinical characteristics, diagnosis, and prevention［J］. Infect Dis Clin North Am, 2019,33（4）:1027⁃1043. doi: 10.1016/j.idc.2019.03.001.
［13］	Osadebe L, Hughes CM, Shongo Lushima R, et al. Enhancing case definitions for surveillance of human monkeypox in the Democratic Republic of Congo［J］. PLoS Negl Trop Dis, 2017,11（9）:e0005857. doi: 10.1371/journal.pntd.0005857.
［14］	Singhal T, Kabra SK, Lodha R. Monkeypox: a review［J］. Indian J Pediatr, 2022,89（10）:955⁃960. doi: 10.1007/s12098⁃022⁃04348⁃0.
［15］	Patel A, Bilinska J, Tam J, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series［J］. BMJ, 2022,378:e072410. doi: 10.1136/bmj⁃2022⁃072410.
［16］	Tarín⁃Vicente EJ, Alemany A, Agud⁃Dios M, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study［J］. Lancet, 2022,400（10353）:661⁃669. doi: 10. 1016/S0140⁃6736（22）01436⁃2.
［17］	Australian Government Department of Heath and Aged Care. Australian national notifiable diseases case definition［EB/OL］. （2022⁃08⁃01）［2022⁃11⁃02］. https://www.health.gov.au/resources/publications/monkeypox⁃virus⁃infection⁃surveillance⁃case⁃definition.
［18］	European Centre for Disease Prevention and Control, World Health Organization European Region. Joint ECDC⁃WHO regional office for Europe monkeypox surveillance bulletin［EB/OL］. （2022⁃09⁃21）［2022⁃11⁃02］. https://www.who.int/europe/publications/m/item/joint⁃ecdc⁃who⁃regional⁃office⁃for⁃europe⁃monkeypox⁃surveillance⁃bulletin⁃⁃21⁃september⁃2022.
［19］	World Heath Organization. Clinical management and infection prevention and control for monkeypox: interim rapid response guidance［EB/OL］. （2022⁃06⁃10）［2022⁃11⁃02］. https://www.who.int/publications/i/item/WHO⁃MPX⁃Clinical⁃and⁃IPC⁃2022.1.
［20］	中华人民共和国国家卫生健康委员会. 猴痘诊疗指南（2022年版）［EB/OL］. （2022⁃06⁃14）［2022⁃11⁃02］. http://www.nhc.gov.cn/yzygj/s7653p/202206/d687b12fe8b84bbfaede2c7a5ca596ec.
	shtml.
［21］	Vaughan AM, Cenciarelli O, Colombe S, et al. A large multi⁃country outbreak of monkeypox across 41 countries in the WHO European Region, 7 March to 23 August 2022［J］. Euro Surveill, 2022,27（36）. doi: 10.2807/1560⁃7917.ES.2022.27.36.2200620.
［22］	Kannan S, Shaik Syed Ali P, Sheeza A. Monkeypox: epidemiology, mode of transmission, clinical features, genetic clades and molecular properties［J］. Eur Rev Med Pharmacol Sci, 2022,26（16）:5983⁃5990. doi: 10.26355/eurrev_202208_29540.
［23］	Harris E. What to know about monkeypox［J］. JAMA, 2022,327（23）:2278⁃2279. doi: 10.1001/jama.2022.9499.
［24］	Tutu van Furth AM, van der Kuip M, van Els AL, et al. Paediatric monkeypox patient with unknown source of infection, the Netherlands, June 2022［J］. Euro Surveill, 2022,27（29）. doi: 10.2807/1560⁃7917.ES.2022.27.29.2200552.
［25］	Damon IK. Status of human monkeypox: clinical disease, epidemiology and research［J］. Vaccine, 2011,29 Suppl 4:D54⁃59. doi: 10.1016/j.vaccine.2011.04.014.
［26］	Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK［J］. Lancet Infect Dis, 2022,22（8）:1153⁃1162. doi: 10.1016/S1473⁃3099（22）00228⁃6.
［27］	Stern D, Olson VA, Smith SK, et al. Rapid and sensitive point⁃of⁃care detection of Orthopoxviruses by ABICAP immunofiltration［J］. Virol J, 2016,13（1）:207. doi: 10.1186/s12985⁃016⁃0665⁃5.
［28］	Diaz JH. The disease ecology, epidemiology, clinical manifestations, management, prevention, and control of increasing human infections with animal ortho poxviruses［J］. Wilderness Environ Med, 2021,32（4）:528⁃536. doi: 10.1016/j.wem.2021.08.003.
［29］	Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management［J］. Viruses, 2022,14（2）. doi: 10.3390/v14020192.
［30］	Hoff NA, Morier DS, Kisalu NK, et al. Varicella coinfection in patients with active monkeypox in the Democratic Republic of the Congo［J］. Ecohealth, 2017,14（3）:564⁃574. doi: 10.1007/s10393⁃017⁃1266⁃5.
［31］	Ramoni S, Maronese CA, Morini N, et al. Syphilis and monkeypox co⁃infection: coincidence, synergy or asymptomatic carriage?［J］. Travel Med Infect Dis, 2022,50:102447. doi: 10.1016/j.tmaid.2022.102447.
［32］	Sherwat A, Brooks JT, Birnkrant D, et al. Tecovirimat and the treatment of monkeypox ⁃ past, present, and future considerations［J］. N Engl J Med, 2022,387（7）:579⁃581. doi: 10.1056/NEJMp2210125.
［33］	Desai AN, Thompson GR 3rd, Neumeister SM, et al. Compassionate use of tecovirimat for the treatment of monkeypox infection［J］. JAMA, 2022,328（13）:1348⁃1350. doi: 10.1001/jama.2022.15336.
［34］	De Clercq E. Cidofovir in the therapy and short⁃term prophylaxis of poxvirus infections［J］. Trends Pharmacol Sci, 2002,23（10）:456⁃458. doi: 10.1016/s0165⁃6147（02）02091⁃6.
［35］	Khawaja F, Batista MV, El Haddad L, et al. Resistant or refractory cytomegalovirus infections after hematopoietic cell trans⁃plantation: diagnosis and management［J］. Curr Opin Infect Dis, 2019,32（6）:565⁃574. doi: 10.1097/QCO.0000000000000607.
［36］	Berhanu A, King DS, Mosier S, et al. Impact of ST⁃246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice［J］. Vaccine, 2010,29（2）:289⁃303. doi: 10.1016/j.vaccine.2010.10.039.
［37］	Russo AT, Berhanu A, Bigger CB, et al. Co⁃administration of tecovirimat and ACAM2000™ in non⁃human primates: effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge［J］. Vaccine, 2020,38（3）:644⁃654. doi: 10.1016/j.vaccine.2019.10.049.
［38］	Perez Duque M, Ribeiro S, Martins JV, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022［J］. Euro Surveill, 2022,27（22）. doi: 10.2807/1560⁃7917.ES.2022.27.22.2200424.
［39］	Iñigo Martínez J, Gil Montalbán E, Jiménez Bueno S, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022［J］. Euro Surveill, 2022,27（27）. doi: 10.2807/1560⁃7917.ES.2022.27.27. 2200471.
［40］	UK Health Security Agency. Investigation into monkeypox outbreak in England: technical briefing 3［EB/OL］. （Updated 2022⁃09⁃23）［2022⁃11⁃02］. https://www.gov.uk/government/publications/monkeypox⁃outbreak⁃technical⁃briefings/investigation⁃into⁃monkeypox⁃outbreak⁃in⁃england⁃technical⁃briefing⁃3.
［41］	Hoffmann C, Jessen H, Wyen C, et al. Clinical characteristics of monkeypox virus infections among men with and without HIV: a large outbreak cohort in Germany［J］. HIV Med, 2022. doi: 10.1111/hiv.13378.
［42］	Mbala PK, Huggins JW, Riu⁃Rovira T, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo［J］. J Infect Dis, 2017,216（7）:824⁃828. doi: 10.1093/infdis/jix260.
［43］	Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events［J］. Paediatr Drugs, 2009,11（5）:309⁃321. doi: 10.2165/11316080⁃000000000⁃00000.

[1]	Jiang Qian, Hu Bin, Chen Yao, Chen Liuqing. Acquired facial hyperpigmented macules in children: a retrospective analysis of clinical and skin imaging features in 131 cases [J]. Chinese Journal of Dermatology, 2025, 58(9): 843-847.
[2]	Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of an antioxidant gel containing tea polyphenols combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(9): 834-838.
[3]	Xu Zhongyi, Xing Xiaoxue, Dong Yaqi, Zhang Chengfeng, Xiang Leihong. Retrospective analysis of clinical manifestations and treatment outcomes in 254 patients with melasma in a tertiary grade-A hospital in Shanghai [J]. Chinese Journal of Dermatology, 2025, 58(9): 808-815.
[4]	Zhu Tingting, Li Weiran, Pan Zhaobing, Liu Hao, Tang Xianfa, Zhu Caihong, Huang Hequn, Duan Dawei, Zhang Ruochen, Chen Xiaojian, Wang Yang, Xue Qian, Zhang Jurui, Yang Lijing, Zhang Xuejun, Huang He, Zhang Bo, . Efficacy of baricitinib combined with ruxolitinib cream in the treatment of six patients with progressive nonsegmental vitiligo: a clinical observation [J]. Chinese Journal of Dermatology, 2025, 58(9): 856-859.
[5]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the diagnosis and treatment of localized scleroderma （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(8): 699-708.
[6]	Acne Study Group of China Dermatologist Association, Dermatology Professional Committee of Chinese Research Hospital Association, Acne Study Group of Dermatology and Venereology Professional Committee of Chinese Association of Integrative Medicine. Chinese expert consensus on clinical severity grading and therapeutic evaluation of acne vulgaris （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(8): 709-714.
[7]	Xue Ke, Chen Jia, Li Bin. Targeted therapy for systemic lupus erythematosus [J]. Chinese Journal of Dermatology, 2025, 58(8): 781-784.
[8]	Lyu Shuying, Wang Ying, Lin Wenjun, Yang Dingquan. Efficacy of combination therapy with tofacitinib in the treatment of alopecia ophiasis: a retrospective analysis of 21 cases [J]. Chinese Journal of Dermatology, 2025, 58(7): 630-635.
[9]	Hair Research Group, Chinese Society of Dermatology. Chinese expert consensus on the diagnosis and treatment of lichen planopilaris/frontal fibrosing alopecia （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(7): 583-590.
[10]	Wei Ran, Li Qinfeng. Novel targeted drugs for the treatment of pediatric alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 650-653.
[11]	Shao Guanghui, Li Yuqian, Chen Qitao, Zhu Qilin, Zhu Jing, Li Zhongming, Du Xufeng, Fan Weixin. Congenital triangular alopecia [J]. Chinese Journal of Dermatology, 2025, 58(7): 668-671.
[12]	Qi-Quan CHEN Song Zhi-Qiang WANG Gang. Guidelines for the diagnosis and treatment of refractory chronic spontaneous urticaria in China （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(6): 485-496.
[13]	Huang Hejin, Li Xinya, He Ziqing, Xi Wenwen, Tang Yujun, Zhang Jianfei, Xiao Xia, Jiang Bin, Yang Feng. Postoperative complications in 3 000 patients with axillary osmidrosis after minimally invasive rotary cutting surgery: a retrospective study [J]. Chinese Journal of Dermatology, 2025, 0(5): 20230291-e0230291.
[14]	The Consensus Development Expert Group on Diagnosis and Treatment of Port-wine Stain in Chinese Children, Pediatric Dermatologist Committee, China Dermatologist Association. Expert consensus on diagnosis and treatment of port-wine stain in children （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 396-404.
[15]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.

Monkeypox: clinical manifestations, diagnosis, treatment and follow-up

PDF

Knowledge

Abstract

Cite this article

share this article

References ［43］

Related Articles 15

Metrics

Comments

Recommended 10